scholarly journals Does fibroblast growth factor 23 correlates with volume status in hemodialysis patients?

2019 ◽  
Vol 8 (4) ◽  
pp. 35-35
Author(s):  
Farzanehsadat Minoo ◽  
Azam Alamdari ◽  
Hamed Karimi
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Volume Overload ◽  
Cross Sectional Study ◽  
Hemodialysis Patients ◽  
Fibroblast Growth ◽  
Cross Sectional ◽  
Measured Volume

Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies. Objectives: This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients. Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis. Results: The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P=0.824). Conclusion: Although this study did not show any association between volume overload and FGF23, further studies are needed to define the role of FGF23 as a volume overload marker.

scholarly journals Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study

2019 ◽  
Vol 20 (9) ◽  
pp. 2292 ◽  
Author(s):  
Swati Gulati ◽  
J. Michael Wells ◽  
Gisel P. Urdaneta ◽  
Kira Balestrini ◽  
Isabel Vital ◽  
...  
Keyword(s):  
Growth Factor ◽  
Lung Function ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Airway Disease ◽  
Cross Sectional Study ◽  
Chronic Obstructive ◽  
Fibroblast Growth ◽  
Cross Sectional ◽  
Fgf 23

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.

Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria

2016 ◽  
Vol 64 (6) ◽  
pp. 1128-1133 ◽  
Author(s):  
Ayca Inci ◽  
Funda Sari ◽  
Melahat Coban ◽  
Refik Olmaz ◽  
Suleyman Dolu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Cross Sectional Study ◽  
Healthy Controls ◽  
Fibroblast Growth ◽  
Cross Sectional ◽  
Patients With Diabetes ◽  
The Relationship

The relationship between soluble Klotho (s-Klotho) levels, fibroblast growth factor 23 (FGF23) levels, and albuminuria in patients with diabetic chronic kidney disease (CKD) remains unclear. A total of 109 patients with type 2 diabetes (mean age 61.63±9.77 years), at the outpatient clinic of the Antalya Research and Training Hospital Nephrology Unit between January and June 2014, as well as 32 healthy controls (mean age 49.53±7.32 years) were enrolled for this cross-sectional study. Patients were classified into three groups according to their urinary albumin creatinine ratio (UACR), normoalbuminuria (UACR<30 mg/g), microalbuminuria (UACR 30–300 mg/g), and macroalbuminuria (UACR>300 mg/g). The blood was analyzed for FGF23, s-Klotho, parathyroid hormone (PTH), P, Ca, creatinine, and 25-hydroxyvitamin D3 (25hD) levels. Creatinine, s-Klotho, FGF23, and PTH levels were significantly higher and 25hD levels were significantly lower in the patient group than in the healthy controls (p<0.001). Between the groups according to UACR, 1-way analysis of variance revealed statistically significant differences for creatinine (p<0.001), 25hD (p<0.001), PTH (p=0.002), Ca (p=0.002), and albumin levels (p<0.001). A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and UACR (r=0.768; p=0.001). In conclusion, the results of the present study suggest that s-Klotho levels are significantly elevated in patients with diabetes and s-Klotho levels decreased with increasing albumin excretion in our patients despite a reduction in estimated glomerular filtration rate.

scholarly journals Serum intact fibroblast growth factor 23 in healthy paediatric population

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 1022-1027
Author(s):  
Malgorzata Stanczyk ◽  
Slawomir Chrul ◽  
Krystyna Wyka ◽  
Marcin Tkaczyk
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Age Groups ◽  
Paediatric Population ◽  
Cross Sectional Study ◽  
Age Group ◽  
Fibroblast Growth ◽  
Cross Sectional ◽  
Fgf23 Level

Abstract Introduction It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children. Material and methods This study was conducted in 121 children aged 0–18 years. Kidney function and intact FGF23 levels in serum were assessed. Differences between age groups and according to gender were analysed. Results The difference in FGF23 between age groups and according to gender was statistically insignificant. In the youngest and the oldest group, a trend to higher FGF23 levels was observed. FGF23 level in girls tended to be higher than boys, apart from the age group between 1 and 4 years. There was a negative correlation between eGFR and FGF23 (r = −0.26, p < 0.05) – strong in girls (r = −0.38, p < 0.05), but not in boys. In each age group, we found no significant correlation between eGFR and FGF23. Conclusions Our study supports the evidence that the FGF23 level in paediatric population is not age or sex dependent. The results can serve as a reference point under clinical conditions and for other studies on the topic.

The role of fibroblast growth factor-23 in left atrial volume

2013 ◽  
Vol 165 (5) ◽  
pp. e21 ◽  
Author(s):  
Supawat Ratanapo ◽  
Wonngarm Kittanamongkolchai ◽  
Narat Srivali ◽  
Saeed Ahmed ◽  
Wisit Cheungpasitporn ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Left Atrial ◽  
Fibroblast Growth Factor 23 ◽  
Left Atrial Volume ◽  
Fibroblast Growth ◽  
Atrial Volume

scholarly journals Plasma intact fibroblast growth factor 23 levels in women with bulimia nervosa: A cross-sectional pilot study

2011 ◽  
Vol 5 (1) ◽  
pp. 7 ◽  
Author(s):  
Makoto Otani ◽  
Yoshiyuki Takimoto ◽  
Junko Moriya ◽  
Kazuhiro Yoshiuchi ◽  
Akira Akabayashi
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Bulimia Nervosa ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Cross Sectional
Sign in / Sign up

Export Citation Format

Share Document